Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Trading Statement

5 Aug 2009 07:00

RNS Number : 8979W
PuriCore Plc
05 August 2009
Β 

ο»Ώ

PuriCore H1 2009 Trading UpdateΒ 

Record Food Safety Shipments

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 5 AugustΒ 2009 -Β PuriCoreΒ (LSE: PURI),Β the life sciences company focused onΒ developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today announcesΒ a trading update covering the six months to 30 June 2009.Β Interim results for this period are expected to be announced on 25 August 2009.Β 

H1 2009Β highlights:

Sales of $19.1 million, a decrease of 2% (an increase of 8% on a constant currency basis)Β (H1 2008: $19.5Β million)

Food Safety sales of $12.6 million, an increase of 16%

Endoscopy sales of $6.1 million, a decrease of 27% (3% on a constant currency basis)

Β 

CashΒ balance as at 30 June 2009 of $15.8 million (increased from the cash balance as at 31 March 2009 of $15.6 million as a result of improved working capital and foreign currency)

Q2 operational cashflow positive

H1 operational cash outflowΒ of $2.7 million (H1 2008: $4.8 million)

Debt reduced $2.7 million in H1 ($1.3 million in Q2)

Β 

Gross profit marginsΒ unchangedΒ compared withΒ H1 2008
Operating expense reductions of 14% (12% net of non-cash share compensation, depreciation and amortisation)Β compared withΒ H1 2008Β 
Record 6-monthΒ shipments ofΒ 614Β Sterilox Food Safety Systems

Post period-end developmentsΒ (see separate release issued today):

Acquisition of Labcaire Systems Ltd., a leading UK supplier and manufacturer of endoscope disinfection equipmentΒ 

Β£2Β million by way of a Placing through the issue ofΒ 10,810,811Β Placing SharesΒ at an Issue Price ofΒ 18.5Β pence per shareΒ 

Outlook

PuriCoreΒ expects to completeΒ the successful integration of Labcaire Systems into the business this year. The Company anticipates delivering full-year results for legacy PuriCore in line with market expectations for revenue growth and operating expenditure improvement. The Directors believe the Company is well positioned for further growth, and PuriCore will continue to make effective use of its balance sheet, including the strategic use of debt financing for leased systems.

Greg Bosch,Β Chief Executive ofΒ PuriCore, said:

Β 

"WeΒ remain confident that weΒ areΒ well-positioned to execute on ourΒ legacy PuriCoreΒ business planΒ and look forward to integrating the Labcaire business in the UK as announced separately today."

Enquiries:

Ben Brewerton

Greg Bosch, CEO

Susan Quigley

Darren Weiss, VP of Finance

Financial Dynamics

PuriCore

+44 (0) 20 7831 3113

+1 484 321 2700

About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safeΒ and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats ofΒ C.difficile,Β E.coli, HIV, Human and Animal Influenza (including H5N1 Avian Influenza),Β Legionella, MRSA,Β M.tuberculosis, Norovirus, andΒ Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford and Clevedon, UK.Β 

To receive additional information on PuriCore, please visit our website atΒ www.puricore.com, which does not form part of this press release.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTEASPSESFNEEE
Date   Source Headline
5th Sep 20114:35 pmRNSPrice Monitoring Extension
23rd Aug 20117:00 amRNSHalf Yearly Report
21st Jul 20117:00 amRNSRe Settlement with Misonix
15th Jun 201110:06 amRNSResult of AGM
18th May 20117:00 amRNSAnnual Information Update
17th May 20114:58 pmRNSUK Division Update
6th May 20117:00 amRNSAnnual Report and Accounts Available
28th Apr 20116:21 pmRNSFinal Results
28th Apr 20116:21 pmRNSInterim Management Statement
4th Apr 20112:29 pmRNSHolding(s) in Company
31st Mar 20114:53 pmRNSHolding(s) in Company
31st Mar 20114:52 pmRNSHolding(s) in Company
31st Mar 20114:51 pmRNSHolding(s) in Company
31st Mar 20117:00 amRNSTotal Voting Rights
22nd Mar 20117:00 amRNSPlacing of New Ordinary Shares
15th Mar 20114:24 pmRNSPotential Sale of Endoscopy Division
4th Feb 201111:51 amRNSBlocklisting Interim Review
2nd Feb 20111:18 pmRNSPre-Close Trading Update
9th Dec 20108:58 amRNSBlocklisting Interim Review
30th Nov 20107:00 amRNSChange of Adviser
8th Nov 20107:00 amRNSInterim Management Statement
29th Oct 20109:56 amRNSResult of General Meeting
11th Oct 20104:00 pmRNSProposed New Long Term Incentive Plan
2nd Sep 20102:44 pmRNSDirector/PDMR Shareholding
31st Aug 20107:00 amRNSHalf Yearly Report
9th Aug 20107:00 amRNSTrading Statement
22nd Jul 20101:36 pmRNSHolding(s) in Company
22nd Jul 20101:30 pmRNSHolding(s) in Company
30th Jun 20109:47 amRNSResult of AGM
21st Jun 20101:10 pmRNSReplacement: Director/PDMR Shareholding
21st Jun 20107:00 amRNSDirector/PDMR Shareholding
16th Jun 20107:00 amRNSBoard Change
14th Jun 20101:38 pmRNS2010 General Meeting Results
14th Jun 20109:16 amRNSAnnual Information Update
28th May 20102:55 pmRNSPublication of Circular
28th May 20107:32 amRNSResumption of Trading
28th May 20107:30 amRNSRestoration
28th May 20107:02 amRNSInterim Management Statement
28th May 20107:01 amRNSFinal Results
28th May 20107:00 amRNSIssue of Secured Convertible Loan Notes
24th May 20102:55 pmRNSHolding(s) in Company
30th Apr 20107:54 amRNSTemporary Suspension
30th Apr 20107:30 amRNSTemporary Suspension - PuriCore Plc
23rd Apr 20107:00 amRNSPuriCore Raises $1.8 Million
24th Feb 20107:00 amRNSBlocklisting Interim Review
20th Jan 20107:00 amRNSTrading Statement
4th Dec 20097:00 amRNSWins Emerging Life Sciences Company of the Year
12th Nov 20097:00 amRNSChange of Adviser
11th Nov 20092:00 pmRNSClinical Results for Vashe Wound Therapy
3rd Nov 20097:00 amRNSInterim Management Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.